OBJECTIVES: To assess the annual frequency of injections of ranibizumab over time for the treatment of retinal diseases in Canada. METHODS: The Rx Dynamics database (IMS Health Canada Inc.) for the Ontario Public Drug Program (OPDP), the Régie de l’assurance-maladie du Québec (RAMQ) and the national Private Drug Plan (PDP) was used for the period ranging from January 2008 to January 2015 to track the mean number of claims per year per patient.  Longitudinal and cross-sectional analyses were performed. Analyses were also performed by indication (wAMD, DME and RVO) when the information was available. The index date was defined as the date of the first ranibizumab claim.  Patients with no active claim of ranibizumab during a specific year were not included in the mean of that year. One claim equals one injection. RESULTS: For the longitudinal analyses, where the three cohorts of patients were followed for 5 consecutive years, the mean number of injections are 5.9, 5.5, 5.6, 5.7 and 5.9 for the OPDP cohort (n=12,944), 5.2, 4.7, 5.5, 5.9 and 5.8 for the RAMQ cohort (n=1,835) and 4.2, 5.1, 5.0, 5.4 and 5.1 for PDP (n=449) cohort.  For the cross-sectional analyses, the mean number of injections for the first year of treatment are 5.9 for the OPDP (n=60,105), 5.9 for RAMQ (n=11,557) and 5.1 for PDP (n=5,292).  In addition, similar results are obtained when the mean number of injections is assessed by retinal conditions. CONCLUSIONS: These results suggest that Canadian patients treated with ranibizumab receive a mean number of injections of 5-6 per year over time.  These results also confirm the uptake of individualized treatment regimen, such as treat and extend, by the Canadian physicians.  All findings and conclusions are those of the author, and are based in part on data licensed from IMS Health Canada Inc. (all rights reserved).